278 related articles for article (PubMed ID: 26703728)
21. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities.
Hallis B; James BA; Shone CC
J Clin Microbiol; 1996 Aug; 34(8):1934-8. PubMed ID: 8818885
[TBL] [Abstract][Full Text] [Related]
22. The biological activity of botulinum neurotoxin type C is dependent upon novel types of ganglioside binding sites.
Strotmeier J; Gu S; Jutzi S; Mahrhold S; Zhou J; Pich A; Eichner T; Bigalke H; Rummel A; Jin R; Binz T
Mol Microbiol; 2011 Jul; 81(1):143-56. PubMed ID: 21542861
[TBL] [Abstract][Full Text] [Related]
23. Studies on botulinum neurotoxins type /C1 and mosaic/DC using Endopep-MS and proteomics.
Moura H; Terilli RR; Woolfitt AR; Gallegos-Candela M; McWilliams LG; Solano MI; Pirkle JL; Barr JR
FEMS Immunol Med Microbiol; 2011 Apr; 61(3):288-300. PubMed ID: 21205003
[TBL] [Abstract][Full Text] [Related]
24. Complexity of botulinum neurotoxins: challenges for detection technology.
Dorner MB; Schulz KM; Kull S; Dorner BG
Curr Top Microbiol Immunol; 2013; 364():219-55. PubMed ID: 23239356
[TBL] [Abstract][Full Text] [Related]
25. Detection of the HA-33 protein in botulinum neurotoxin type G complex by mass spectrometry.
Kalb SR; Baudys J; Barr JR
BMC Microbiol; 2015 Oct; 15():227. PubMed ID: 26494251
[TBL] [Abstract][Full Text] [Related]
26. Comparative functional analysis of mice after local injection with botulinum neurotoxin A1, A2, A6, and B1 by catwalk analysis.
Moritz MS; Tepp WH; Inzalaco HN; Johnson EA; Pellett S
Toxicon; 2019 Sep; 167():20-28. PubMed ID: 31181297
[TBL] [Abstract][Full Text] [Related]
27. Critical Analysis of Neuronal Cell and the Mouse Bioassay for Detection of Botulinum Neurotoxins.
Pellett S; Tepp WH; Johnson EA
Toxins (Basel); 2019 Dec; 11(12):. PubMed ID: 31817843
[TBL] [Abstract][Full Text] [Related]
28. Enhanced detection of type C botulinum neurotoxin by the Endopep-MS assay through optimization of peptide substrates.
Wang D; Krilich J; Baudys J; Barr JR; Kalb SR
Bioorg Med Chem; 2015 Jul; 23(13):3667-73. PubMed ID: 25913863
[TBL] [Abstract][Full Text] [Related]
29. P19 embryonal carcinoma cells exhibit high sensitivity to botulinum type C and D/C mosaic neurotoxins.
Tsukamoto K; Arimitsu H; Ochi S; Nakamura K; Tanaka Y; Nuemket N; Taniguchi K; Kozaki S; Tsuji T
Microbiol Immunol; 2012 Oct; 56(10):664-72. PubMed ID: 22738015
[TBL] [Abstract][Full Text] [Related]
30. Proposed BoNT/A and /B Peptide Substrates Cannot Detect Multiple Subtypes in the Endopep-MS Assay.
Kalb SR; Baudys J; Kiernan K; Wang D; Becher F; Barr JR
J Anal Toxicol; 2020 Mar; 44(2):173-179. PubMed ID: 31287544
[TBL] [Abstract][Full Text] [Related]
31. Comparison of extracellular and intracellular potency of botulinum neurotoxins.
Cai F; Adrion CB; Keller JE
Infect Immun; 2006 Oct; 74(10):5617-24. PubMed ID: 16988237
[TBL] [Abstract][Full Text] [Related]
32. Zebrafish Sensitivity to Botulinum Neurotoxins.
Chatla K; Gaunt PS; Petrie-Hanson L; Ford L; Hanson LA
Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27153088
[TBL] [Abstract][Full Text] [Related]
33. Light Chain Diversity among the Botulinum Neurotoxins.
Gardner AP; Barbieri JT
Toxins (Basel); 2018 Jul; 10(7):. PubMed ID: 30004421
[TBL] [Abstract][Full Text] [Related]
34. Detection of botulinum neurotoxin A in a spiked milk sample with subtype identification through toxin proteomics.
Kalb SR; Goodnough MC; Malizio CJ; Pirkle JL; Barr JR
Anal Chem; 2005 Oct; 77(19):6140-6. PubMed ID: 16194071
[TBL] [Abstract][Full Text] [Related]
35. Development of sensitive colorimetric capture elisas for Clostridium botulinum neurotoxin serotypes A and B.
Szílagyi M; Rivera VR; Neal D; Merrill GA; Poli MA
Toxicon; 2000 Mar; 38(3):381-9. PubMed ID: 10669027
[TBL] [Abstract][Full Text] [Related]
36. Ex vivo inhibition of Clostridium botulinum neurotoxin types B, C, E, and F by small molecular weight inhibitors.
Montgomery VA; Ahmed SA; Olson MA; Mizanur RM; Stafford RG; Roxas-Duncan VI; Smith LA
Toxicon; 2015 May; 98():12-9. PubMed ID: 25707753
[TBL] [Abstract][Full Text] [Related]
37. Unique ganglioside binding by botulinum neurotoxins C and D-SA.
Kroken AR; Karalewitz AP; Fu Z; Baldwin MR; Kim JJ; Barbieri JT
FEBS J; 2011 Dec; 278(23):4486-96. PubMed ID: 21554541
[TBL] [Abstract][Full Text] [Related]
38. Effect of adjuvants on antibody titer of synthetic recombinant light chain of botulinum neurotoxin type B and its diagnostic potential for botulism.
Jain S; Ponmariappan S; Kumar O; Singh L
J Microbiol Biotechnol; 2011 Jul; 21(7):719-27. PubMed ID: 21791958
[TBL] [Abstract][Full Text] [Related]
39. Mass Spectrometric Detection of Bacterial Protein Toxins and Their Enzymatic Activity.
Kalb SR; Boyer AE; Barr JR
Toxins (Basel); 2015 Aug; 7(9):3497-511. PubMed ID: 26404376
[TBL] [Abstract][Full Text] [Related]
40. Validation of a clinical assay for botulinum neurotoxins through mass spectrometric detection.
Hoyt KM; Barr JR; Hopkins AO; Dykes JK; Lúquez C; Kalb SR
J Clin Microbiol; 2024 Jun; 62(6):e0162923. PubMed ID: 38687021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
